RGRX (Regenerx Biopharmaceuticals) Total Liabilities: $3.93 Mil (As of Mar. 2023)


What is Regenerx Biopharmaceuticals Total Liabilities?

Regenerx Biopharmaceuticals RGRX Total Liabilities is $3.93 Mil as of Mar. 2023.

Regenerx Biopharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2023 was $3.93 Mil.

Regenerx Biopharmaceuticals's quarterly Total Liabilities increased from Sep. 2022 ($3.72 Mil) to Dec. 2022 ($3.83 Mil) and increased from Dec. 2022 ($3.83 Mil) to Mar. 2023 ($3.93 Mil).

Regenerx Biopharmaceuticals's annual Total Liabilities increased from Dec. 2020 ($3.38 Mil) to Dec. 2021 ($3.52 Mil) and increased from Dec. 2021 ($3.52 Mil) to Dec. 2022 ($3.83 Mil).

Regenerx Biopharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Regenerx Biopharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerx Biopharmaceuticals Total Liabilities Chart

Regenerx Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.49 3.05 3.38 3.52 3.83

Regenerx Biopharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.53 3.60 3.72 3.83 3.93

Regenerx Biopharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Regenerx Biopharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.554+(1.403+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+1.871+0+0)
=3.83

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=0.382--3.445
=3.83

Regenerx Biopharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.8+(0.28+-0.00099999999999989
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+1.852+0+0)
=3.93

Total Liabilities=Total Assets (Q: Mar. 2023 )-Total Equity (Q: Mar. 2023 )
=0.187--3.744
=3.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $3.93 Mil mean?
Regenerx Biopharmaceuticals (RGRX) has a Total Liabilities of $3.93 Mil as of Mar. 2023. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Regenerx Biopharmaceuticals and its competitors.
Is Regenerx Biopharmaceuticals' Total Liabilities too high?
Regenerx Biopharmaceuticals' current Total Liabilities is $3.93 Mil.
How does Regenerx Biopharmaceuticals' Total Liabilities compare to MYMX and RGMP?
Regenerx Biopharmaceuticals' Total Liabilities of $3.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Regenerx Biopharmaceuticals and its competitors. Regenerx Biopharmaceuticals's current Total Liabilities is $3.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerx Biopharmaceuticals stock overvalued right now?
Regenerx Biopharmaceuticals (RGRX) has a current Total Liabilities of $3.93 Mil. The current Total Liabilities is $3.93 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Regenerx Biopharmaceuticals (RGRX), the current Total Liabilities is $3.93 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerx Biopharmaceuticals Business Description

Address 15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.